Advice
Following a full submission
levetiracetam (Keppra®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.
In the pivotal study, there was a significantly greater reduction in the primary generalised tonic-clonic seizure frequency in the levetiracetam group compared with the placebo group. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their decision to resubmit.
Download detailed advice106KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 396/07
- Indication:
- as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 September 2007